OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Pharmacokinetics and Pharmacodynamics is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Population pharmacokinetic and pharmacodynamic model of propofol externally validated in Korean elderly subjects	40
Translational physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies	34
Learning pharmacometric covariate model structures with symbolic regression networks	32
Achieving big with small: quantitative clinical pharmacology tools for drug development in pediatric rare diseases	29
Advancing inclusive healthcare through PBPK modelling: predicting the impact of CYP genotypes and enzyme ontogenies on infant exposures of venlafaxine and its active metabolite O-desmethylvenlafaxine	29
Semi-mechanistic modeling of resistance development to β-lactam and β-lactamase-inhibitor combinations	25
Model-informed approach to estimate treatment effect in placebo-controlled clinical trials using an artificial intelligence-based propensity weighting methodology to account for non-specific responses	23
Mixed effect estimation in deep compartment models: Variational methods outperform first-order approximations	19
Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials	18
Correction: Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease	18
Early exposure-response modeling of an interferon-beta monoclonal antibody (dazukibart) in adults with dermatomyositis	17
ADPO: automatic-differentiation-assisted parametric optimization	16
Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of	16
Translational population target binding model for the anti-FcRn fragment antibody efgartigimod	16
Imputation of missing clock times – application to procalcitonin concentration time course after birth	15
Informatics for toxicokinetics	15
Comparison of the power and type 1 error of total score models for drug effect detection in clinical trials	15
Population pharmacokinetics and pharmacodynamics of efmarodocokin alfa (IL-22Fc)	15
Current practices for QSP model assessment: an IQ consortium survey	15
Training the next generation of pharmacometric modelers: a multisector perspective	14
Oral docetaxel plus encequidar – A pharmacokinetic model and evaluation against IV docetaxel	13
Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms	12
Mechanistic inference of the metabolic rates underlying $$^{13}$$C breath test curves	12
Generative models for synthetic data generation: application to pharmacokinetic/pharmacodynamic data	12
External validation of population pharmacokinetic models of adalimumab in adult patients with inflammatory bowel disease: towards model-informed precision dosing	11

Latent variable indirect response modeling of clinical efficacy endpoints with combination therapy: application to guselkumab and golimumab in patients with ulcerative colitis	11
Risks encountered when not adjusting for diurnal variation and food effect in QTcF analysis based on phase I data	11
A system pharmacology Boolean network model for the TLR4-mediated inflammatory response in early sepsis	10
Development of a novel rabeprazole modified release formulation to reduce the dosing frequency: A trial and triumph with physiologically based biopharmaceutics modeling	10
Uncertainty undermines the validity of antimicrobial pharmacodynamics	9
Translational pharmacokinetic and pharmacodynamic modelling of the anti-ADAMTS-5 NANOBODY® (M6495) using the neo-epitope ARGS as a biomarker	9
Application of model-informed drug development (MIDD) for dose selection in regulatory submissions for drug approval in Japan	9
Maximum a posteriori Bayesian methods out-perform non-compartmental analysis for busulfan precision dosing	9
Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension	9
Expansion of platform physiologically-based pharmacokinetic model for monoclonal antibodies towards different preclinical species: cats, sheep, and dogs	9
A translational physiologically-based pharmacokinetic model for MMAE-based antibody-drug conjugates	9
Scoping review of the role of pharmacometrics in model-informed drug development	8
Five multivariate Duchenne muscular dystrophy progression models bridging six-minute walk distance and MRI relaxometry of leg muscles	8
Advancing cancer drug development with mechanistic mathematical modeling: bridging the gap between theory and practice	8
Thanks to our Reviewers of 2022!	8
Leveraging large language models in pharmacometrics: evaluation of NONMEM output interpretation and simulation capabilities	8
Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab	8
Correction to: Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials	8
Characterization of CAR-T cellular kinetics and efficacy in solid tumor patients with and without prior lymphodepletion chemotherapy using a PBPK-PD model	7
QSP model for AAV-mediated antibody delivery in rat brain	7
Population pharmacokinetic/pharmacodynamic modeling of nifekalant injection with varies dosing plan in Chinese volunteers: a randomized, blind, placebo-controlled study	7
PBPK model for antibody disposition in mouse brain: validation using large-pore microdialysis data	7
A quantitative systems pharmacology model of plasma kallikrein-kinin system dysregulation in hereditary angioedema	7
APOE4 genotypes and the trajectory of biomarkers, neuroimaging, and cognitive measures in Alzheimer’s Disease: A mixed-effects disease progression model	7
Sampling from covariate distribution may not always be necessary in PK/PD simulations: illustrative examples with antibiotics	7
An automated pipeline to generate initial estimates for population Pharmacokinetic base models	7
Stochastic pharmacodynamics of a heterogeneous tumour-cell population	7
A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy	7
A QSP PDE model of ADC transport and kinetics in a growing or shrinking tumor	6
Subgroup identification-based model selection to improve the predictive performance of individualized dosing	6
JPKPD October Special Issue - Commentary	6
ChatGPT and Gemini large language models for pharmacometrics with NONMEM: comment	6
Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates	6
Computing optimal drug dosing with OptiDose: implementation in NONMEM	6
The impact of misspecified covariate models on inclusion and omission bias when using fixed effects and full random effects models	6
A physics-informed neural network approach for estimating population-level pharmacokinetic parameters from aggregated concentration data	6
Correction to: Classical structural identifiability methodology applied to low-dimensional dynamic systems in receptor theory	6